213 related articles for article (PubMed ID: 31429781)
1. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
[TBL] [Abstract][Full Text] [Related]
2. Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study.
Zhan Y; Shen L; Xu W; Wu X; Zhang W; Wang J; Li X; Yang Y; Tian X; Xu KF
Orphanet J Rare Dis; 2018 Feb; 13(1):34. PubMed ID: 29458386
[TBL] [Abstract][Full Text] [Related]
3. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Young L; Lee HS; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Swigris JJ; Taveira-DaSilva AM; Krischer JP; Trapnell BC; McCormack FX;
Lancet Respir Med; 2013 Aug; 1(6):445-52. PubMed ID: 24159565
[TBL] [Abstract][Full Text] [Related]
4. COPD assessment test as a possible tool for evaluating health-related quality of life in lymphangioleiomyomatosis.
Kato M; Kanehiro Y; Yoshimi K; Kodama Y; Sekiya M; Sato T; Takahashi K; Seyama K;
Respir Investig; 2018 Nov; 56(6):480-488. PubMed ID: 30143460
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and Treatment Monitoring Potential of Serum Vascular Endothelial Growth Factor-D in Lymphangioleiomyomatosis.
Mou Y; Ye L; Wang J; Yee MS; Song YL; Zhu L; Jin ML
Lymphology; 2016 Sep; 49(3):140-9. PubMed ID: 29906075
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y
Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.
El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Peters E; Haughey M; Bienfang D; Jones AM; Julien-Williams P; Cui Y; Villalba JA; Bagwe S; Maurer R; Rosas IO; Moss J; Henske EP
Chest; 2017 Jun; 151(6):1302-1310. PubMed ID: 28192114
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
Takada T; Mikami A; Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Akasaka K; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Sugimoto C; Arai T; Hattori N; Watanabe K; Tamada T; Yoshizawa H; Akazawa K; Tanaka T; Yagi K; Young LR; McCormack FX; Nakata K
Ann Am Thorac Soc; 2016 Nov; 13(11):1912-1922. PubMed ID: 27513278
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience.
Revilla-López E; Berastegui C; Méndez A; Sáez-Giménez B; Ruiz de Miguel V; López-Meseguer M; Monforte V; Bravo C; Pujana MA; Ramon MA; Gómez-Ollés S; Roman A;
Sci Rep; 2021 May; 11(1):10171. PubMed ID: 33986388
[TBL] [Abstract][Full Text] [Related]
13. The St. George's Respiratory Questionnaire in lymphangioleiomyomatosis.
Xu KF; Wang L; Tian XL; Gui YS; Peng M; Cai BQ; Zhu YJ
Chin Med Sci J; 2010 Sep; 25(3):140-5. PubMed ID: 21180274
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.
Ando K; Kurihara M; Kataoka H; Ueyama M; Togo S; Sato T; Doi T; Iwakami S; Takahashi K; Seyama K; Mikami M
Respir Investig; 2013 Sep; 51(3):175-83. PubMed ID: 23978644
[TBL] [Abstract][Full Text] [Related]
17. St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis.
Swigris JJ; Lee HS; Cohen M; Inoue Y; Moss J; Singer LG; Young LR; McCormack FX;
Chest; 2013 Jun; 143(6):1671-1678. PubMed ID: 23328755
[TBL] [Abstract][Full Text] [Related]
18. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
[TBL] [Abstract][Full Text] [Related]
19. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
Neurohr C; Hoffmann AL; Huppmann P; Herrera VA; Ihle F; Leuschner S; von Wulffen W; Meis T; Baezner C; Leuchte H; Baumgartner R; Zimmermann G; Behr J
Respir Res; 2011 May; 12(1):66. PubMed ID: 21600034
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.
Yoon HY; Hwang JJ; Kim DS; Song JW
Orphanet J Rare Dis; 2018 Nov; 13(1):204. PubMed ID: 30428897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
